Non-randomized open trial of eicosapentaenoic acid (EPA), an omega-3 fatty acid, in ten people with chronic epilepsy

Alan W. C. Yuen*, Dominique Flugel, Annkathrin Poepel, Gail S. Bell, Janet L. Peacock, Josemir W. Sander

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Abstract

This is a non-randomized open assessment of eicosapentaenoic acid (EPA) supplementation in ten people (five males) with refractory focal seizures. Each received 1000 mg of EPA daily for 3 months. Six people had fewer seizures during the supplementation period compared with baseline (range 12 to 59% reduction) and one other person had markedly reduced seizure severity. The mean reduction in seizure frequency was 16% (95% CI - 10% to 35%, p=0.26). With the small number of participants and open nature of the study, interpretation of the results is difficult, but a possible weak effect of EPA on seizures cannot be discounted. Further examination of EPA supplementation should be undertaken with larger numbers of people in controlled trials. Higher doses and longer duration of treatment should be considered. (C) 2011 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)370-372
Number of pages3
JournalEpilepsy & Behavior
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 2012

Keywords

  • Epilepsy
  • Omega-3 fatty acids
  • Eicosapentaenoic acid
  • EPA
  • Supplementation
  • Clinical trial
  • POLYUNSATURATED FATTY-ACIDS
  • DOUBLE-BLIND
  • ETHYL-EICOSAPENTAENOATE
  • KETOGENIC DIET
  • SCHIZOPHRENIA
  • DEPRESSION
  • CHILDREN

Fingerprint

Dive into the research topics of 'Non-randomized open trial of eicosapentaenoic acid (EPA), an omega-3 fatty acid, in ten people with chronic epilepsy'. Together they form a unique fingerprint.

Cite this